Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

INTRODUCTION: Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric symptoms have not been systemically quantified using structured scales. This...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:AIDS Res Ther
Autors principals: Chan, Phillip, Goh, Orlanda, Kroon, Eugène, Colby, Donn, Sacdalan, Carlo, Pinyakorn, Suteeraporn, Prueksakaew, Peeriya, Reiss, Peter, Ananworanich, Jintanat, Valcour, Victor, Spudich, Serena, Paul, Robert
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945418/
https://ncbi.nlm.nih.gov/pubmed/31907064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-019-0257-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars